Organigram Holdings Inc. (TSE:OGI - Get Free Report) Senior Officer Paolo De Luca sold 12,014 shares of the firm's stock in a transaction dated Thursday, October 24th. The shares were sold at an average price of C$2.52, for a total value of C$30,275.28.
Paolo De Luca also recently made the following trade(s):
- On Wednesday, September 11th, Paolo De Luca sold 13,835 shares of Organigram stock. The shares were sold at an average price of C$2.54, for a total value of C$35,140.90.
- On Friday, August 16th, Paolo De Luca sold 10,266 shares of Organigram stock. The stock was sold at an average price of C$2.76, for a total value of C$28,334.16.
Organigram Price Performance
Shares of OGI opened at C$2.55 on Wednesday. The stock has a 50 day moving average of C$2.47 and a 200-day moving average of C$2.40. Organigram Holdings Inc. has a 52 week low of C$1.36 and a 52 week high of C$3.95. The firm has a market cap of C$276.85 million, a price-to-earnings ratio of -1.02, a PEG ratio of 0.42 and a beta of 1.13. The company has a current ratio of 6.95, a quick ratio of 2.62 and a debt-to-equity ratio of 1.13.
Organigram (TSE:OGI - Get Free Report) last released its earnings results on Tuesday, August 13th. The company reported C$0.03 earnings per share for the quarter, beating the consensus estimate of C($0.07) by C$0.10. Organigram had a negative net margin of 153.80% and a negative return on equity of 54.53%. The firm had revenue of C$41.06 million during the quarter, compared to analyst estimates of C$39.20 million. As a group, analysts forecast that Organigram Holdings Inc. will post 0.1632373 EPS for the current year.
Wall Street Analysts Forecast Growth
War on Elon Escalates…
From Porter & Company | Ad
A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites.
And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.
One company holds a near-total monopoly on it.
Separately, Canaccord Genuity Group raised their price target on shares of Organigram from C$3.25 to C$3.60 and gave the stock a "speculative buy" rating in a research report on Wednesday, August 14th.
Get Our Latest Analysis on Organigram
Organigram Company Profile
(
Get Free Report)
Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
